Clinical Trials Logo

Clinical Trial Summary

Regular blood transfusions are essential for the management of haematological conditions such as β-thalassemia major. As a result, however, patients with these conditions are susceptible to the development of transfusion-dependent iron overload (hemosiderosis or secondary iron overload


Clinical Trial Description

In the absence of a naturally occurring physiological mechanism for the removal of excess iron in the body, life-long treatment and adherence to iron chelation therapy (ICT) are necessary to prevent the morbidity and mortality that may result if excess iron is allowed to .

Deferasirox (DFO),is the oldest available form of ICT used by patients with transfusion-dependent disorders. Improvements in ICT administration convenience and tolerability are expected to improve patient's satisfaction with ICT and Health Related Quality of Life (HRQOL), thus promoting adherence to ICT regimens and potentially reducing iron overload-related morbidity/mortality and associated healthcare costs ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03358498
Study type Observational
Source Assiut University
Contact Osama A Ibrahiem, Prof
Phone 00201006372498
Email oibrahiem@yahoo.com
Status Not yet recruiting
Phase N/A
Start date December 1, 2017
Completion date March 1, 2020

See also
  Status Clinical Trial Phase
Completed NCT00560820 - Phase I Study to Examine the Effect of Deferasirox on Renal Hemodynamics in β-thalassemia Patients With Transfusional Iron Overload Phase 1
Recruiting NCT05773729 - Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent Beta-thalassemia N/A
Recruiting NCT05864170 - the Safety and Efficacy Evaluation of HGI-001 Injection in Patients With Transfusion-Dependent β-Thalassemia Early Phase 1
Completed NCT04054921 - Safety Study for Beta Thalassemia Subjects on PTG-300 Phase 2
Not yet recruiting NCT06440603 - EKLF Gene Expression in β-thalassemia
Recruiting NCT06465550 - A Phase 1 Study of the Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cell in β-thalassemia Major Phase 1
Completed NCT03802201 - Study of PTG-300 in Non-Transfusion Dependent and Transfusion-Dependent Beta-Thalassemia Subjects With Chronic Anemia Phase 2
Recruiting NCT05745532 - Safety and Efficacy Evaluation of β-globin Restored Autologous Hematopoietic Stem Cells in β-thalassemia Major Patients Early Phase 1
Recruiting NCT05494333 - Correlation Between Pulmonary Functions and Physical Fitness in Children With β-thalassemia